MedWatch

New factory takes AGC Danmark to another level within the corporation

Demand for medication production is now so high that AGC Biologics' Danish unit expects to sell the output of almost full production capacity at the company's new factory within three years after commissioning, expectedly in 2023.

Construction of the new factory in Copenhagen is a major project for AGC Biologics, both locally and for the group as a whole. Opførslen af en ny fabrik i København er et stort projekt for AGC Biologics, både lokalt og for koncernen som hele. Photo shows, from left to right, Technical Director Kasper Møller, Copenhagen Site Lead Andrea Porchia, and VP of Technical Operations Christian Christensen. | Photo: Lars Thornblad

When AGC Biologics' new production facilities enter operation in 2023 and 300 new personnel are hired, the Danish division will be among the largest within the corporation, says Copenhagen Site Head Andrea Porchia.

"Within AGC Biologics, we will clearly become one of the largest production units with this new factory, but expansions are also taking pace at other sites, so it's difficult to say precisely where we will land, but it will be around the top," she says.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs